author_facet Ochsenreither, Sebastian
Majeti, Ravindra
Loeb, Keith
Stirewalt, Derek L.
Keilholz, Ulrich
Weissman, Irving L
Greenberg, Philip D
Ochsenreither, Sebastian
Majeti, Ravindra
Loeb, Keith
Stirewalt, Derek L.
Keilholz, Ulrich
Weissman, Irving L
Greenberg, Philip D
author Ochsenreither, Sebastian
Majeti, Ravindra
Loeb, Keith
Stirewalt, Derek L.
Keilholz, Ulrich
Weissman, Irving L
Greenberg, Philip D
spellingShingle Ochsenreither, Sebastian
Majeti, Ravindra
Loeb, Keith
Stirewalt, Derek L.
Keilholz, Ulrich
Weissman, Irving L
Greenberg, Philip D
Journal of Clinical Oncology
Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
Cancer Research
Oncology
author_sort ochsenreither, sebastian
spelling Ochsenreither, Sebastian Majeti, Ravindra Loeb, Keith Stirewalt, Derek L. Keilholz, Ulrich Weissman, Irving L Greenberg, Philip D 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2523 <jats:p> 2523 </jats:p><jats:p> Background: Targeted T-cell therapy represents a more specific and less toxic alternative to allogeneic stem cell transplantation for providing a cytotoxic anti-leukemic response to eliminate the leukemic stem cell (LSC) compartment in acute myeloid leukemia (AML). The aim of this study was to identify a leukemia-associated antigen that is both immunogenic and exhibits selective high expression in AML LSCs. Methods: Expression microarrays of leukemic and normal cells were used to identify suitable candidate genes. Cyclin-A1 appeared to be differentially expressed, and was further analyzed by quantitative RT-PCR, intracellular FACS staining, and immunofluorescence microscopy. T-cell clones specific for cyclin-A1 were generated by stimulation in vitro with an overlapping peptide library, followed by cloning of responding cells. Specificity of the clones was documented by intracellular IFNg and tetramer staining. Cytotoxicity was determined by chromium release and caspase-3 cleavage assays. Results: To identify target candidates with a suitable expression pattern, microarray data from LSCs, hematopoietic cells and healthy tissues were compared. Cyclin-A1 was found to be selectively expressed in LSCs of &gt;50% of AML patients, but minimally expressed in normal tissues with exception of testis. Using dendritic cells and monocytes pulsed with a cyclin-A1 peptide library, T-cells were generated against eight cyclin-A1 oligopeptides. Two HLA A2-restricted epitopes were further characterized, and specific T-cell clones recognized both peptide-pulsed target cells and the HLA A2-positive AML line THP-1. Furthermore, cyclin-A1-specific CD8 T-cells lysed primary AML cells. Conclusions: Cyclin-A1, known to be important in meiosis, is expressed in AML LSCs and testis and can be targeted by T-cells. Thus, cyclin-A1 is the first prototypic LSC-associated leukemia-testis-antigen. Cyclin-A1 already has been shown to be leukemogenic in mice and to promote proliferation and survival in AML blasts. This pro-oncogenic activity, together with high expression levels and a multitude of immunogenic epitopes, make it a promising target for T-cell based therapy approaches. </jats:p> Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells. Journal of Clinical Oncology
doi_str_mv 10.1200/jco.2012.30.15_suppl.2523
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4yNTIz
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4yNTIz
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint American Society of Clinical Oncology (ASCO), 2012
imprint_str_mv American Society of Clinical Oncology (ASCO), 2012
issn 0732-183X
1527-7755
issn_str_mv 0732-183X
1527-7755
language English
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
match_str ochsenreither2012cyclina1expressioninacutemyeloidleukemiastemcellsanditsrepresentationasanimmunogenicantigenthatcanbetargetedbycytotoxictcells
publishDateSort 2012
publisher American Society of Clinical Oncology (ASCO)
recordtype ai
record_format ai
series Journal of Clinical Oncology
source_id 49
title Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_unstemmed Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_full Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_fullStr Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_full_unstemmed Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_short Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_sort cyclin-a1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic t cells.
topic Cancer Research
Oncology
url http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2523
publishDate 2012
physical 2523-2523
description <jats:p> 2523 </jats:p><jats:p> Background: Targeted T-cell therapy represents a more specific and less toxic alternative to allogeneic stem cell transplantation for providing a cytotoxic anti-leukemic response to eliminate the leukemic stem cell (LSC) compartment in acute myeloid leukemia (AML). The aim of this study was to identify a leukemia-associated antigen that is both immunogenic and exhibits selective high expression in AML LSCs. Methods: Expression microarrays of leukemic and normal cells were used to identify suitable candidate genes. Cyclin-A1 appeared to be differentially expressed, and was further analyzed by quantitative RT-PCR, intracellular FACS staining, and immunofluorescence microscopy. T-cell clones specific for cyclin-A1 were generated by stimulation in vitro with an overlapping peptide library, followed by cloning of responding cells. Specificity of the clones was documented by intracellular IFNg and tetramer staining. Cytotoxicity was determined by chromium release and caspase-3 cleavage assays. Results: To identify target candidates with a suitable expression pattern, microarray data from LSCs, hematopoietic cells and healthy tissues were compared. Cyclin-A1 was found to be selectively expressed in LSCs of &gt;50% of AML patients, but minimally expressed in normal tissues with exception of testis. Using dendritic cells and monocytes pulsed with a cyclin-A1 peptide library, T-cells were generated against eight cyclin-A1 oligopeptides. Two HLA A2-restricted epitopes were further characterized, and specific T-cell clones recognized both peptide-pulsed target cells and the HLA A2-positive AML line THP-1. Furthermore, cyclin-A1-specific CD8 T-cells lysed primary AML cells. Conclusions: Cyclin-A1, known to be important in meiosis, is expressed in AML LSCs and testis and can be targeted by T-cells. Thus, cyclin-A1 is the first prototypic LSC-associated leukemia-testis-antigen. Cyclin-A1 already has been shown to be leukemogenic in mice and to promote proliferation and survival in AML blasts. This pro-oncogenic activity, together with high expression levels and a multitude of immunogenic epitopes, make it a promising target for T-cell based therapy approaches. </jats:p>
container_issue 15_suppl
container_start_page 2523
container_title Journal of Clinical Oncology
container_volume 30
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792323454875205632
geogr_code not assigned
last_indexed 2024-03-01T11:34:05.576Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Cyclin-A1+expression+in+acute+myeloid+leukemia+stem+cells+and+its+representation+as+an+immunogenic+antigen+that+can+be+targeted+by+cytotoxic+T+cells.&rft.date=2012-05-20&genre=article&issn=1527-7755&volume=30&issue=15_suppl&spage=2523&epage=2523&pages=2523-2523&jtitle=Journal+of+Clinical+Oncology&atitle=Cyclin-A1+expression+in+acute+myeloid+leukemia+stem+cells+and+its+representation+as+an+immunogenic+antigen+that+can+be+targeted+by+cytotoxic+T+cells.&aulast=Greenberg&aufirst=Philip+D&rft_id=info%3Adoi%2F10.1200%2Fjco.2012.30.15_suppl.2523&rft.language%5B0%5D=eng
SOLR
_version_ 1792323454875205632
author Ochsenreither, Sebastian, Majeti, Ravindra, Loeb, Keith, Stirewalt, Derek L., Keilholz, Ulrich, Weissman, Irving L, Greenberg, Philip D
author_facet Ochsenreither, Sebastian, Majeti, Ravindra, Loeb, Keith, Stirewalt, Derek L., Keilholz, Ulrich, Weissman, Irving L, Greenberg, Philip D, Ochsenreither, Sebastian, Majeti, Ravindra, Loeb, Keith, Stirewalt, Derek L., Keilholz, Ulrich, Weissman, Irving L, Greenberg, Philip D
author_sort ochsenreither, sebastian
container_issue 15_suppl
container_start_page 2523
container_title Journal of Clinical Oncology
container_volume 30
description <jats:p> 2523 </jats:p><jats:p> Background: Targeted T-cell therapy represents a more specific and less toxic alternative to allogeneic stem cell transplantation for providing a cytotoxic anti-leukemic response to eliminate the leukemic stem cell (LSC) compartment in acute myeloid leukemia (AML). The aim of this study was to identify a leukemia-associated antigen that is both immunogenic and exhibits selective high expression in AML LSCs. Methods: Expression microarrays of leukemic and normal cells were used to identify suitable candidate genes. Cyclin-A1 appeared to be differentially expressed, and was further analyzed by quantitative RT-PCR, intracellular FACS staining, and immunofluorescence microscopy. T-cell clones specific for cyclin-A1 were generated by stimulation in vitro with an overlapping peptide library, followed by cloning of responding cells. Specificity of the clones was documented by intracellular IFNg and tetramer staining. Cytotoxicity was determined by chromium release and caspase-3 cleavage assays. Results: To identify target candidates with a suitable expression pattern, microarray data from LSCs, hematopoietic cells and healthy tissues were compared. Cyclin-A1 was found to be selectively expressed in LSCs of &gt;50% of AML patients, but minimally expressed in normal tissues with exception of testis. Using dendritic cells and monocytes pulsed with a cyclin-A1 peptide library, T-cells were generated against eight cyclin-A1 oligopeptides. Two HLA A2-restricted epitopes were further characterized, and specific T-cell clones recognized both peptide-pulsed target cells and the HLA A2-positive AML line THP-1. Furthermore, cyclin-A1-specific CD8 T-cells lysed primary AML cells. Conclusions: Cyclin-A1, known to be important in meiosis, is expressed in AML LSCs and testis and can be targeted by T-cells. Thus, cyclin-A1 is the first prototypic LSC-associated leukemia-testis-antigen. Cyclin-A1 already has been shown to be leukemogenic in mice and to promote proliferation and survival in AML blasts. This pro-oncogenic activity, together with high expression levels and a multitude of immunogenic epitopes, make it a promising target for T-cell based therapy approaches. </jats:p>
doi_str_mv 10.1200/jco.2012.30.15_suppl.2523
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4yNTIz
imprint American Society of Clinical Oncology (ASCO), 2012
imprint_str_mv American Society of Clinical Oncology (ASCO), 2012
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 0732-183X, 1527-7755
issn_str_mv 0732-183X, 1527-7755
language English
last_indexed 2024-03-01T11:34:05.576Z
match_str ochsenreither2012cyclina1expressioninacutemyeloidleukemiastemcellsanditsrepresentationasanimmunogenicantigenthatcanbetargetedbycytotoxictcells
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
physical 2523-2523
publishDate 2012
publishDateSort 2012
publisher American Society of Clinical Oncology (ASCO)
record_format ai
recordtype ai
series Journal of Clinical Oncology
source_id 49
spelling Ochsenreither, Sebastian Majeti, Ravindra Loeb, Keith Stirewalt, Derek L. Keilholz, Ulrich Weissman, Irving L Greenberg, Philip D 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2523 <jats:p> 2523 </jats:p><jats:p> Background: Targeted T-cell therapy represents a more specific and less toxic alternative to allogeneic stem cell transplantation for providing a cytotoxic anti-leukemic response to eliminate the leukemic stem cell (LSC) compartment in acute myeloid leukemia (AML). The aim of this study was to identify a leukemia-associated antigen that is both immunogenic and exhibits selective high expression in AML LSCs. Methods: Expression microarrays of leukemic and normal cells were used to identify suitable candidate genes. Cyclin-A1 appeared to be differentially expressed, and was further analyzed by quantitative RT-PCR, intracellular FACS staining, and immunofluorescence microscopy. T-cell clones specific for cyclin-A1 were generated by stimulation in vitro with an overlapping peptide library, followed by cloning of responding cells. Specificity of the clones was documented by intracellular IFNg and tetramer staining. Cytotoxicity was determined by chromium release and caspase-3 cleavage assays. Results: To identify target candidates with a suitable expression pattern, microarray data from LSCs, hematopoietic cells and healthy tissues were compared. Cyclin-A1 was found to be selectively expressed in LSCs of &gt;50% of AML patients, but minimally expressed in normal tissues with exception of testis. Using dendritic cells and monocytes pulsed with a cyclin-A1 peptide library, T-cells were generated against eight cyclin-A1 oligopeptides. Two HLA A2-restricted epitopes were further characterized, and specific T-cell clones recognized both peptide-pulsed target cells and the HLA A2-positive AML line THP-1. Furthermore, cyclin-A1-specific CD8 T-cells lysed primary AML cells. Conclusions: Cyclin-A1, known to be important in meiosis, is expressed in AML LSCs and testis and can be targeted by T-cells. Thus, cyclin-A1 is the first prototypic LSC-associated leukemia-testis-antigen. Cyclin-A1 already has been shown to be leukemogenic in mice and to promote proliferation and survival in AML blasts. This pro-oncogenic activity, together with high expression levels and a multitude of immunogenic epitopes, make it a promising target for T-cell based therapy approaches. </jats:p> Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells. Journal of Clinical Oncology
spellingShingle Ochsenreither, Sebastian, Majeti, Ravindra, Loeb, Keith, Stirewalt, Derek L., Keilholz, Ulrich, Weissman, Irving L, Greenberg, Philip D, Journal of Clinical Oncology, Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells., Cancer Research, Oncology
title Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_full Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_fullStr Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_full_unstemmed Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_short Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
title_sort cyclin-a1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic t cells.
title_unstemmed Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.
topic Cancer Research, Oncology
url http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2523